
This study reports the five-year survival outcomes of patients with extensive-stage small cell lung cancer (SCLC) treated with atezolizumab plus chemotherapy in the IMpower133 and IMbrella A trials. The median follow-up was 59.4 months, with 12% of patients achieving five-year overall survival. The analysis offers the first long-term survival data for SCLC treated with this immunotherapy regimen, despite limitations due to the small sample size.
Like
Save
Share